Skip to main content
. 2012 May 24;17(6):747–755. doi: 10.1634/theoncologist.2011-0458

Table 2.

Prospective clinical trials of lanreotide in neuroendocrine tumors

graphic file with name onc00612-1074-t02.jpg

aMedian duration of treatment includes all drug regimens.

Abbreviations: ATG, autogel; ECOG, Eastern Cooperative Oncology Group; GEP-NET, gastroenteropancreatic neuroendocrine tumor; GI-NET, gastrointestinal neuroendocrine tumor; LA, long acting; LAR, long-acting repeatable; NET, neuroendocrine tumor; NS, not specified; pNET, pancreatic neuroendocrine tumor; PS, performance status; SR, slow-release; TBD, to be determined.